Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Global, Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase 2 Study to Evaluate the Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC Administered by a Prefilled Syringe in Kidney Transplant Recipients With Antibody-Mediated Rejection

NCT06503731 is registered in ClinicalTrials.gov with argenx as lead sponsor.

NCT NCT06503731
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06503731 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Global, Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase 2 Study to Evaluate the Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC Administered by a Prefilled Syringe in Kidney Transplant Recipients With Antibody-Mediated Rejection
Lead sponsor
argenx
Phase
Phase 2
Overall status
Active, not recruiting
Start date
August 30, 2024
Completion date
November 30, 2027
Enrollment
33 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

antibody-mediated rejection